From Evaluating Novel Targets to Meaningful Endpoints, Collaborating on Regulatory Strategies, and Effectively Engaging Diverse Patient Populations to Advance Efficacious Kidney Therapies from Discovery to Patients
Welcome to your Exclusive Opportunity to Build Relationships and Network with Rare & Genetic Renal Disease Experts
Accelerating Transformative Therapeutics in the Renal Landscape
The Nephrology landscape is buzzing with innovation! Major players like Novartis, Vertex, Otsuka, and Regulus are making significant strides in clinical trials, while cutting-edge novel modalities and technologies are being tested in preclinical studies by Arbor Biotech, Maze Therapeutics, and ProteinQure to name a few.
The Rare & Genetic Kidney Disease Drug Development Summit returns for its 5th year to unite the leading minds of the renal renaissance from biopharma and regulators to academic key opinion leaders and patient advocacy groups. This meeting will harness the energy and dedication to real impactful advancements in rare renal drug development with patients at the forefront.
Join us at the 2025 meeting to gain insights from 25+ expert speakers covering the entire spectrum of rare renal drug development, from discovery and preclinical to clinical development. Participate in three dedicated workshops for active discussion on key topics including target identification, mechanistic biology, kidney-on-a-chip models, trial design, recruitment & retention strategies, and patient empowerment. This comprehensive program spans a broad spectrum of renal programs, including FSGS, PKD, Alport Syndrome, and IgAN, among others. Join 80+ industry experts this September to access exclusive insights into therapeutic development across the rare renal field and bring actionable learnings and competitive intelligence back to your team.
World-Class Speaker Faculty Includes:
Kristin Van Goor
Executive Director & Head of Global Regulatory Policy & Innovation
Takeda Pharmaceutical
Previously Attending Companies Include:
Testimonials:
"I gained great value from interacting with the expert attendees and speakers working on rare renal diseases. This is a unique community and it was wonderful to have so many gathered together."
"This a great meeting to align with the latest biopharma & pharma companies in the rare kidney space on clinical trials and the regulatory landscape.” "
"Excellent sessions and values at the workshops, new biotech updates, FDA perspectives, and patient advocate organizations."
"It was a well planned, well developed conference with pertinent information presented."
Our Partners:
